Toripalimab (NCT06592599)

Name: Toripalimab trial for Nasopharyngeal Carcinoma (NCT06592599)
Uploaded: 2026-10-31T22:53:28.823Z
Duration: 1 min 24 s
Description: Toripalimab trial for Nasopharyngeal Carcinoma (NCT06592599). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06592599.

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC): a one-minute explainerNCT065925991 min

Toripalimab trial for Nasopharyngeal Carcinoma (NCT06592599). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with untreated, locally advanced Epstein-Barr-virus-positive nasopharyngeal cancer, without distant metastases. Prior radiation overlapping the treatment area excludes participation.

The idea: toripalimab blocks the PD1 immune brake. Three cycles with gemcitabine and docetaxel precede radiation with weekly cisplatin. After chemoradiation, oral capecitabine continues for one year, alongside up to nine toripalimab doses three weeks apart. Researchers assess whether patients complete planned induction treatment and radiation, alongside safety and cancer outcomes.

This phase 2 study plans 24 patients. Dimitrios Colevas leads at Stanford, Palo Alto, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.